Robert W. Baird Forecasts Strong Price Appreciation for LivaNova (NASDAQ:LIVN) Stock

LivaNova (NASDAQ:LIVN) had its target price hoisted by stock analysts at Robert W. Baird from $61.00 to $63.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Robert W. Baird’s price objective indicates a potential upside of 24.88% from the company’s current price.

Other analysts have also recently issued reports about the stock. Wall Street Zen upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 9th. Barclays increased their price objective on LivaNova from $55.00 to $58.00 and gave the company an “equal weight” rating in a research report on Thursday, August 21st. The Goldman Sachs Group set a $55.00 target price on LivaNova and gave the stock a “neutral” rating in a report on Wednesday, October 1st. Needham & Company LLC reaffirmed a “buy” rating and set a $64.00 target price on shares of LivaNova in a report on Wednesday, September 3rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of LivaNova in a research report on Wednesday, October 8th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, LivaNova presently has a consensus rating of “Moderate Buy” and a consensus price target of $60.00.

LivaNova Price Performance

Shares of LivaNova stock opened at $50.45 on Thursday. LivaNova has a 52 week low of $32.48 and a 52 week high of $58.91. The company has a current ratio of 1.29, a quick ratio of 1.09 and a debt-to-equity ratio of 0.31. The stock has a market cap of $2.75 billion, a PE ratio of -12.97 and a beta of 1.00. The company’s 50-day moving average price is $54.02 and its two-hundred day moving average price is $48.25.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $1.11 earnings per share for the quarter, beating the consensus estimate of $0.91 by $0.20. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. The company had revenue of $357.80 million during the quarter, compared to analyst estimates of $342.32 million. During the same quarter last year, the firm posted $0.90 EPS. The business’s revenue for the quarter was up 12.5% on a year-over-year basis. LivaNova has set its FY 2025 guidance at 3.800-3.90 EPS. As a group, sell-side analysts anticipate that LivaNova will post 2.85 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of LIVN. Primecap Management Co. CA raised its position in LivaNova by 0.7% during the second quarter. Primecap Management Co. CA now owns 4,641,352 shares of the company’s stock valued at $208,954,000 after buying an additional 32,942 shares during the period. Vanguard Group Inc. boosted its position in LivaNova by 13.5% during the 1st quarter. Vanguard Group Inc. now owns 2,666,880 shares of the company’s stock worth $104,755,000 after acquiring an additional 316,993 shares during the period. AQR Capital Management LLC boosted its position in LivaNova by 30.5% during the 2nd quarter. AQR Capital Management LLC now owns 2,049,820 shares of the company’s stock worth $92,201,000 after acquiring an additional 478,525 shares during the period. Geode Capital Management LLC grew its stake in LivaNova by 1.3% during the 2nd quarter. Geode Capital Management LLC now owns 1,429,740 shares of the company’s stock valued at $64,374,000 after acquiring an additional 18,551 shares in the last quarter. Finally, Artisan Partners Limited Partnership grew its stake in LivaNova by 112.9% during the 2nd quarter. Artisan Partners Limited Partnership now owns 1,247,609 shares of the company’s stock valued at $56,167,000 after acquiring an additional 661,480 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.